Drug · FAERS side-effect profile with label screen

Bisoprolol side effects: what 135,055 FDA adverse event reports show

Bisoprolol Fumarate · 1,251 reaction terms · 552,781 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Label matched

Bisoprolol Fumarate (Bisoprolol Fumarate)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

135,055 reports · 97% serious · 14,918 with death outcome · 48% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Bisoprolol fumarate is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.

FDA label, Indications and Usage

What it is

DESCRIPTION Bisoprolol fumarate USP is a synthetic, beta 1 -selective (cardioselective) adrenoceptor blocking agent.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 2Likely indication confounding 2Reporting / coding artifact 2Lab value / disease marker 5Not in label — unassessed 29

What the badges mean

Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,211 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Right atrial hypertrophy	90	684.9 421.9–1,111.9ROR 685.4 · calibrated p 5e-14 ✓	122.2 EB05 102.4 · IC025 +5.9 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=90 · ♀ 0% (drug 48%) · 100% consumer	not reported in cached trials
Cardiospasm	404	418.3 346.4–505.2ROR 419.6 · calibrated p 5e-13 ✓	111.8 EB05 102.9 · IC025 +6.5 3/3 methods agree	Not in label — unassessed	serious n=404	not reported in cached trials
Fractional exhaled nitric oxide increased	109	267.6 195.9–365.5ROR 267.8 · calibrated p 8e-11 ✓	96.1 EB05 81.9 · IC025 +5.8 3/3 methods agree	Not in label — unassessed	serious n=109 · ♀ 0% (drug 48%)	not reported in cached trials
Immunisation	264	245.0 201.7–297.7ROR 245.5 · calibrated p 9e-11 ✓	93.9 EB05 84.8 · IC025 +6.1 3/3 methods agree	Not in label — unassessed	serious n=264	not reported in cached trials
Palmoplantar keratoderma	396	191.3 165.0–221.8ROR 191.9 · calibrated p 7e-10 ✓	85.0 EB05 78.2 · IC025 +6.1 3/3 methods agree	Not in label — unassessed	serious n=396	not reported in cached trials
Neurologic neglect syndrome	204	89.0 74.9–105.7ROR 89.1 · calibrated p 3e-7 ✓	56.2 EB05 50.1 · IC025 +5.4 3/3 methods agree	Not in label — unassessed	serious n=204 · ♀ 100% (drug 48%) · 100% clinician	not reported in cached trials
Vital capacity decreased	125	59.5 48.4–73.1ROR 59.5 · calibrated p 5e-6 ✓	42.8 EB05 36.8 · IC025 +4.9 3/3 methods agree	Not in label — unassessed	serious n=125 · ♀ 100% (drug 48%)	not reported in cached trials
Amaurosis fugax	264	50.7 44.1–58.3ROR 50.8 · calibrated p 1e-5 ✓	38.2 EB05 34.5 · IC025 +5.0 3/3 methods agree	Not in label — unassessed	serious n=264 · 93% clinician	not reported in cached trials
Carotid artery thrombosis	208	49.9 42.6–58.3ROR 49.9 · calibrated p 2e-5 ✓	37.7 EB05 33.6 · IC025 +4.9 3/3 methods agree	Not in label — unassessed	serious n=208 · ♀ 100% (drug 48%) · 100% clinician	not reported in cached trials
Atrial tachycardia	503	48.5 43.9–53.6ROR 48.7 · calibrated p 2e-5 ✓	37.0 EB05 34.3 · IC025 +5.0 3/3 methods agree	Not in label — unassessed	serious n=502	not reported in cached trials
Systemic infection	338	39.5 35.0–44.5ROR 39.5 · calibrated p 6e-5 ✓	31.5 EB05 28.8 · IC025 +4.7 3/3 methods agree	Not in label — unassessed	serious n=338 · 100% clinician	not reported in cached trials
Reversible airways obstruction	103	38.7 31.2–48.1ROR 38.7 · calibrated p 8e-5 ✓	30.9 EB05 26.2 · IC025 +4.4 3/3 methods agree	Not in label — unassessed	serious n=103 · ♀ 100% (drug 48%)	not reported in cached trials
Pruritus genital	423	34.3 30.9–38.1ROR 34.4 · calibrated p 1e-4 ✓	28.2 EB05 26.0 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=421	not reported in cached trials
Steroid dependence	146	32.1 26.8–38.3ROR 32.1 · calibrated p 2e-4 ✓	26.6 EB05 23.2 · IC025 +4.3 3/3 methods agree	Not in label — unassessed	serious n=146 · ♀ 0% (drug 48%) · 100% clinician	not reported in cached trials
Catarrh	148	30.9 25.9–36.8ROR 30.9 · calibrated p 2e-4 ✓	25.8 EB05 22.5 · IC025 +4.3 3/3 methods agree	Not in label — unassessed	serious n=148 · ♀ 0% (drug 48%) · 100% clinician	not reported in cached trials
N-terminal prohormone brain natriuretic peptide increased	221	28.9 25.1–33.4ROR 29.0 · calibrated p 3e-4 ✓	24.4 EB05 21.8 · IC025 +4.3 3/3 methods agree	Lab value / disease marker	serious n=217 · ♀ 28% (drug 48%)	not reported in cached trials
Bronchial secretion retention	197	28.5 24.5–33.2ROR 28.6 · calibrated p 4e-4 ✓	24.1 EB05 21.4 · IC025 +4.3 3/3 methods agree	Not in label — unassessed	serious n=197	not reported in cached trials
Adjustment disorder	193	26.8 23.0–31.3ROR 26.9 · calibrated p 5e-4 ✓	22.9 EB05 20.3 · IC025 +4.2 3/3 methods agree	Not in label — unassessed	serious n=192 · ♀ 100% (drug 48%) · 100% clinician	not reported in cached trials
Product monitoring error	190	23.6 20.2–27.5ROR 23.6 · calibrated p 1e-3 ✓	20.5 EB05 18.2 · IC025 +4.0 3/3 methods agree	Reporting / coding artifact	serious n=189 · 100% clinician	not reported in cached trials
Bronchial wall thickening	96	23.6 19.0–29.2ROR 23.6 · calibrated p 0.001 ✓	20.5 EB05 17.3 · IC025 +3.9 3/3 methods agree	Not in label — unassessed	serious n=96 · ♀ 0% (drug 48%) · 100% consumer	not reported in cached trials
Sputum culture positive	104	22.3 18.1–27.4ROR 22.3 · calibrated p 0.001 ✓	19.5 EB05 16.6 · IC025 +3.8 3/3 methods agree	Lab value / disease marker	serious n=104 · ♀ 100% (drug 48%)	not reported in cached trials
Cardiac failure chronic	514	21.2 19.4–23.3ROR 21.3 · calibrated p 0.001 ✓	18.7 EB05 17.4 · IC025 +4.1 3/3 methods agree	Labeled (related wording) related wording	serious n=514 · 92% clinician	not reported in cached trials
Carotid arteriosclerosis	123	21.1 17.5–25.5ROR 21.1 · calibrated p 0.002 ✓	18.6 EB05 16.0 · IC025 +3.8 3/3 methods agree	Not in label — unassessed	serious n=123 · ♀ 0% (drug 48%)	not reported in cached trials
Bradyarrhythmia	196	21.0 18.0–24.3ROR 21.0 · calibrated p 0.002 ✓	18.5 EB05 16.4 · IC025 +3.9 3/3 methods agree	Not in label — unassessed	serious n=195 · 100% clinician	not reported in cached trials
Carotid artery occlusion	433	20.7 18.8–22.9ROR 20.8 · calibrated p 0.002 ✓	18.4 EB05 16.9 · IC025 +4.0 3/3 methods agree	Not in label — unassessed	serious n=433	not reported in cached trials
Aortic valve stenosis	187	18.0 15.5–21.0ROR 18.0 · calibrated p 0.003 ✓	16.2 EB05 14.3 · IC025 +3.7 3/3 methods agree	Not in label — unassessed	serious n=186	not reported in cached trials
Myoglobin blood increased	160	18.0 15.3–21.2ROR 18.0 · calibrated p 0.003 ✓	16.2 EB05 14.2 · IC025 +3.7 3/3 methods agree	Lab value / disease marker	serious n=160 · ♀ 0% (drug 48%)	not reported in cached trials
Right ventricular hypertrophy	95	18.0 14.5–22.2ROR 18.0 · calibrated p 0.004 ✓	16.1 EB05 13.6 · IC025 +3.6 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=95 · ♀ 0% (drug 48%) · 100% consumer	not reported in cached trials
Obstructive sleep apnoea syndrome	142	17.5 14.7–20.8ROR 17.5 · calibrated p 0.004 ✓	15.7 EB05 13.7 · IC025 +3.6 3/3 methods agree	Not in label — unassessed	serious n=142 · ♀ 0% (drug 48%)	not reported in cached trials
Tension headache	431	17.2 15.6–19.0ROR 17.3 · calibrated p 0.004 ✓	15.6 EB05 14.4 · IC025 +3.8 3/3 methods agree	Labeled (related wording) related wording	serious n=430	not reported in cached trials
Systolic dysfunction	104	16.9 13.8–20.7ROR 16.9 · calibrated p 0.005 ✓	15.3 EB05 12.9 · IC025 +3.5 3/3 methods agree	Not in label — unassessed	serious n=104 · ♀ 0% (drug 48%) · 100% clinician	not reported in cached trials
Sleep terror	400	16.2 14.6–18.0ROR 16.3 · calibrated p 0.005 ✓	14.7 EB05 13.6 · IC025 +3.7 3/3 methods agree	Not in label — unassessed	serious n=400	not reported in cached trials
Pulmonary function test abnormal	148	16.2 13.6–19.1ROR 16.2 · calibrated p 0.005 ✓	14.7 EB05 12.8 · IC025 +3.5 3/3 methods agree	Reporting / coding artifact	serious n=148 · ♀ 0% (drug 48%)	not reported in cached trials
Bloody discharge	108	16.0 13.1–19.5ROR 16.0 · calibrated p 0.006 ✓	14.5 EB05 12.3 · IC025 +3.5 3/3 methods agree	Not in label — unassessed	serious n=108 · ♀ 100% (drug 48%) · 100% clinician	not reported in cached trials
Diastolic dysfunction	285	15.6 13.8–17.6ROR 15.7 · calibrated p 0.006 ✓	14.2 EB05 12.9 · IC025 +3.6 3/3 methods agree	Not in label — unassessed	serious n=283 · ♀ 22% (drug 48%)	not reported in cached trials
Left ventricular dysfunction	595	15.1 13.9–16.5ROR 15.2 · calibrated p 0.007 ✓	13.8 EB05 12.9 · IC025 +3.6 3/3 methods agree	Not in label — unassessed	serious n=595	not reported in cached trials
Brain natriuretic peptide increased	275	15.1 13.4–17.1ROR 15.2 · calibrated p 0.007 ✓	13.8 EB05 12.5 · IC025 +3.6 3/3 methods agree	Lab value / disease marker	serious n=272 · ♀ 20% (drug 48%)	not reported in cached trials
International normalised ratio fluctuation	186	15.0 12.9–17.5ROR 15.1 · calibrated p 0.007 ✓	13.7 EB05 12.1 · IC025 +3.5 3/3 methods agree	Lab value / disease marker	serious n=186 · ♀ 100% (drug 48%)	not reported in cached trials
Sinus node dysfunction	154	14.2 12.0–16.7ROR 14.2 · calibrated p 0.009 ✓	13.0 EB05 11.3 · IC025 +3.4 3/3 methods agree	Not in label — unassessed	serious n=154 · 100% clinician	not reported in cached trials
Tachyarrhythmia	208	14.0 12.2–16.2ROR 14.0 · calibrated p 0.009 ✓	12.9 EB05 11.5 · IC025 +3.4 3/3 methods agree	Not in label — unassessed	serious n=207	not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

Concept	Reports	PRR 95% CI	Reading
Arrhythmia / qt	7,390	6.16.0–6.3	signal
Hyponatraemia	3,059	6.15.9–6.3	signal
Heart failure	5,550	4.94.8–5.1	signal
Kidney injury	13,323	4.64.6–4.7	signal
Rhabdomyolysis / myopathy	2,320	4.54.4–4.7	signal
Gi bleeding	4,674	4.03.9–4.2	signal
Interstitial lung disease	1,892	3.13.0–3.2	signal
Anaemia	5,642	3.02.9–3.0	signal
Severe cutaneous reaction	1,274	2.72.5–2.8	signal
Myocardial infarction	3,225	2.52.4–2.6	signal
Stroke	3,877	2.42.4–2.5	signal
Fall / fracture	5,652	2.32.3–2.4	signal
Hypoglycaemia	1,341	2.22.1–2.3	signal
Liver injury	4,150	2.22.1–2.2	signal
Tendon disorder	518	2.11.9–2.3	raised
Anaphylaxis / angioedema	1,686	2.12.0–2.2	signal

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Bisoprolol as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

NCT03730116 — Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril (N=1909, phase n/a; 8 AE terms posted; arms: the Patients With HT and Concomitant Sta)

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Dyspnoea (shortness of breath)	9,172	2.5 2.5–2.6ROR 2.7 · calibrated p 0.749	2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.0 · serious PRR 2.1	not reported in cached trials
Acute kidney injury (sudden kidney damage)	7,220	7.7 7.5–7.9ROR 8.1 · calibrated p 0.065	7.4 EB05 7.2 · IC025 +2.8 3/3 methods agree	Not in label — unassessed	age-adj. PRR 5.3 · serious PRR 4.4 · 94% clinician	not reported in cached trials
Fatigue (tiredness)	7,142	1.4 1.4–1.5ROR 1.5 · calibrated p 0.612	1.4 EB05 1.4 · IC025 +0.5	Labeled adverse reaction exact term	age-adj. PRR 1.2 · serious PRR 1.5	not reported in cached trials
Diarrhoea (diarrhea)	6,637	1.6 1.6–1.6ROR 1.6 · calibrated p 0.732	1.6 EB05 1.6 · IC025 +0.6	Labeled adverse reaction exact term	age-adj. PRR 1.3 · serious PRR 1.6	not reported in cached trials
Nausea	6,432	1.3 1.2–1.3ROR 1.3 · calibrated p 0.495	1.3 EB05 1.2 · IC025 +0.3	Labeled adverse reaction exact term	age-adj. PRR 1.2 · serious PRR 1.4	not reported in cached trials
Dizziness	6,198	1.9 1.9–2.0ROR 2.0 · calibrated p 0.939	1.9 EB05 1.9 · IC025 +0.9	Labeled adverse reaction exact term	age-adj. PRR 1.5 · serious PRR 2.0	NCT03730116: 2/1,909 (0.1%) on Bisoprolol (serious AE)
Drug interaction	5,779	5.8 5.7–6.0ROR 6.0 · calibrated p 0.147	5.7 EB05 5.5 · IC025 +2.5 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 4.2 · serious PRR 3.7	not reported in cached trials
Off label use (used outside approved label)	5,707	1.0 1.0–1.0ROR 1.0 · calibrated p 0.321	1.0 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC	Reporting / coding artifact	age-adj. PRR 0.9 · serious PRR 1.1	not reported in cached trials
Hypotension (low blood pressure)	5,454	4.3 4.2–4.4ROR 4.5 · calibrated p 0.302	4.2 EB05 4.1 · IC025 +2.0 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 3.1 · serious PRR 2.9	NCT03730116: 2/1,909 (0.1%) on Bisoprolol (serious AE)
Fall	5,398	2.5 2.5–2.6ROR 2.6 · calibrated p 0.767	2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree	Not in label — unassessed	age-adj. PRR 1.5 · serious PRR 1.8	not reported in cached trials
Vomiting	5,008	1.7 1.6–1.7ROR 1.7 · calibrated p 0.764	1.7 EB05 1.6 · IC025 +0.7	Labeled adverse reaction exact term	age-adj. PRR 1.6 · serious PRR 1.4	not reported in cached trials
Malaise (feeling unwell)	4,930	1.7 1.7–1.8ROR 1.8 · calibrated p 0.817	1.7 EB05 1.7 · IC025 +0.8	Labeled adverse reaction exact term	age-adj. PRR 1.5 · serious PRR 1.7	not reported in cached trials
Asthenia (weakness)	4,856	2.0 2.0–2.1ROR 2.1 · calibrated p 0.974	2.0 EB05 2.0 · IC025 +1.0	Labeled adverse reaction exact term	age-adj. PRR 1.4 · serious PRR 1.7	not reported in cached trials
Drug ineffective (drug did not work)	4,786	0.6 0.5–0.6ROR 0.5 · calibrated p 0.064	0.6 EB05 0.6 · IC025 -0.9 PRR-only: not supported by EBGM or IC	Reporting / coding artifact	age-adj. PRR 0.7 · serious PRR 0.9	not reported in cached trials
Headache	4,461	1.1 1.1–1.1ROR 1.1 · calibrated p 0.380	1.1 EB05 1.1 · IC025 +0.1	Labeled adverse reaction exact term	age-adj. PRR 1.1 · serious PRR 1.3	not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Cardiospasm — n=404, PRR 418.3
Fractional exhaled nitric oxide increased — n=109, PRR 267.6
Immunisation — n=264, PRR 245.0
Palmoplantar keratoderma — n=396, PRR 191.3
Neurologic neglect syndrome — n=204, PRR 89.0
Vital capacity decreased — n=125, PRR 59.5
Amaurosis fugax — n=264, PRR 50.7
Carotid artery thrombosis — n=208, PRR 49.9
Atrial tachycardia — n=503, PRR 48.5
Systemic infection — n=338, PRR 39.5

✓ A hand-written Bradford Hill causality assessment exists for this drug: Tenofovir disoproxil fumarate ↔ Bone loss.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Bisoprolol?

In FDA FAERS, the most frequently co-reported reaction terms for Bisoprolol are dyspnoea, acute kidney injury, fatigue, diarrhoea, nausea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Bisoprolol have an FDA boxed warning?

No. The FDA label retrieved for Bisoprolol has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Bisoprolol causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 200ab93b-6ad3-46cb-8f57-db056a14de16, effective 20250516; matched on openfda.generic_name.exact:"BISOPROLOL FUMARATE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 1,251 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath
ClinicalTrials.gov API v2 (query BISOPROLOL, results-bearing studies sorted by enrollment)

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.